Merck’s Keytruda has received FDA approval to expand its use in lung cancer
The US Food and Drug Administration has approved the expanded use of Merck & Co’s blockbuster immunotherapy Keytruda in early-stage patients with non-small cell lung cancer who can have their tumours surgically removed.
POPULAR POSTS
LIVE STREAM
